News
News Archive
- Publication of largest Light Chain Escape – Multiple Myeloma study to date03 February 2009
- Serum free light chain assays now on Roche cobas 600027 January 2009
- Anti-C1q assay is an important addition to panel for SLE diagnosis20 January 2009
- Automated Analyser for Serum/Plasma Protein Analysis07 January 2009
- New International guidelines clarify recommendations for using serum free light chain analysis08 December 2008
- New paper suggests sFLC assays aid assessment of acute renal failure01 December 2008
- NEW 5th edition Serum Free Light Chain Analysis (plus Hevylite)17 November 2008
- Hematology Meeting Reports of Proceedings of Biennial 2008 Conference03 November 2008
- First myeloma kidney patient recruited onto EuLITE clinical trial09 June 2008
- Biennial 2008 - Serum Free Light Chain Symposium14 May 2008
- New Cystatin C assay for Roche Modular P18 March 2008
- Independent Review discusses Value of Serum Free Light Chain Assays11 February 2008
- Serum FLC ratio can help assess risk in patients with Smouldering Multiple Myeloma24 January 2008
- Serum free light chain assay recommended in initial investigation of myeloma19 October 2007
- New Hib (Haemophilus influenzae type b) Antibody Avidity test03 September 2007
- Freelite™ assay wins Queen’s Award11 May 2007
- New Freelite™ assays for COBAS Integra® 400 Plus09 April 2007
- Still using Urine for Multiple Myeloma investigation?23 January 2007
- Serum free light chains in new uniform response criteria23 August 2006
- Serum Free Light Chain Analysis - 4th Edition21 August 2006
- New Guidelines - Freelite™ is acceptable alternative to urine02 May 2006
- Rapid Measurement of RID Rings19 April 2006
- New Single Plate Complement RID Kits18 April 2006
- Automated IgD assay for Behring BN™II06 March 2006
- Freelite more sensitive than urine IFE13 February 2006
- Serum free light chain assays for Bayer Advia® 165012 February 2006
- Freelite gains reimbursement in South Korea06 January 2006
- Improve detection of B-cell dyscrasias05 October 2005
- Identify your low risk MGUS patients *28 July 2005
- 3rd Edition Serum Free Light Chain Analysis06 May 2005
- EuroMedLab Freelite Workshop28 February 2005
- 2005/2006 Clinical Products Catalogue25 February 2005
- Asia Tsunami Donation04 January 2005
- Freelite recommended for amyloidosis19 July 2004
- bjh - Freelite & AL amyloidosis28 January 2004
- Free light chain assays for Olympus AU10 December 2003
- New Book - Serum Free Light Chain Assays10 December 2003
- Replacing discontinued Beckman Endo RID kits07 May 2003
- Lancet publishes new Bence Jones myeloma test21 February 2003
- New Clinical Catalogue 2003/2004 19 February 2003
- High Sensitivity IgG Subclass Reagents06 January 2003
- Immunobiological Reagents Catalogue 2003/403 January 2003
- AACC comments New test proves effective in identifying markers of B-cell tumors04 September 2002
- New FREELITE kits for Hitachi 911 & 91203 September 2002
- Prizewinning FREELITE study15 May 2002
- Mayo Clinic publishes FREELITE Multiple Myeloma data21 March 2002
- Diphtheria IgG ELISA kit15 January 2002
- New MININEPH kits for serum protein assays07 January 2002
- FREELITE - For Multiple Myeloma diagnosis and monitoring.21 November 2001
03 February 2009
Publication of largest Light Chain Escape – Multiple Myeloma study to date
'Light-chain escape-multiple myeloma' - an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.
A. Kühnemund et al. J Cancer Res Clin Oncol 2008, Sep 18.
doi 10.1007/s00432-008-0470-7
This article describes 10 patients with Intact Immunoglobulin Multiple Myeloma who developed light chain escape at relapse (LCE-MM). Their Multiple Myeloma appeared stable, as judged by conventional monitoring of intact Ig levels, but developed severe organ dysfunction as a consequence of initially undetected light chain progression. Serum free light chain (SFLC) changes were one of the measures studied.
The authors commented "Classic diagnostics, such as electrophoresis and quantitative Ig measurements proved futile to detect LC-progression, whereas SFLC's were reliable markers"
"Our report suggests that early detection of LCE-MM by means of serial SFLC measurements may prevent unnecessary complications, allows to detect unusual relapse manifestations in the era of intensive and biological therapy options and possibly also permits to improve treatment results in LCE-MM."
Request your copy from Binding Site or contact us requesting MKG487.
More information on Freelite and Light Chain Escape plus Clinical Evidence for SFLCs in other B cell dyscrasia.
.jpg)